Ciba have pointed out to us that there is no regulation in Norway reserving rifampicin for the treatment of tuberculous infections, as we had stated. In fact, to reduce the chance of drug resistant organisms emerging, Ciba has deliberately refrained from recommending the use of its drug for other purposes in Norway.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.